Skip to main content

Table 1 Publication characteristics and citation rates for included trials of thrombolytics for stroke

From: Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis

Trial Year published Patients enrolled Location Journal Intervention Jadad score Result Total citations Citations per year
NINDS [11] 1995 624 US NEJM IV tPA 5 Positive 6622 330
ECASS III [12] 2008 821 Europe NEJM IV tPA 5 Positive 2458 335
ECASS [13] 1995 620 Europe JAMA IV tPA 5 Neutral 2138 106
ECASS II [14] 1998 800 Europe, Australia, NZ Lancet IV tPA 5 Neutral 1768 102
EPITHET [15] 2008 101 Australia, NZ, Belgium, UK Lancet Neurology IV tPA 5 Neutral 561 72
IST-3 [16] 2012 3035 Europe, Canada, Mexico, Australia Lancet IV tPA 3 Neutral 380 104
ATLANTIS B [17] 1999 613 US, Canada JAMA IV tPA 5 Negative 820 51
ATLANTIS A [18] 2000 142 US Stroke IV tPA 5 Negative 276 18
PROACT II [19] 1999 180 US, Canada JAMA IA pro-urokinase 3 Positive 2287 142
DIAS [20] 2005 104 Europe, Australia, Singapore Stroke IV desmoteplase 5 Positive 749 69
DIAS-2 [21] 2009 193 Australia, Europe, US, Canada, China, Singapore Lancet Neurology IV desmoteplase 5 Neutral 332 49
MELT [22] 2007 114 Japan Stroke IA urokinase 3 Neutral 282 34
ASK [23] 1996 340 Australia JAMA IV streptokinase 5 Negative 328 17
MAST-E [24] 1996 310 Europe NEJM IV streptokinase 5 Negative 421 22
MAST-I [25] 1995 622 Europe Lancet IV streptokinase 3 Negative 551 27
  1. IA intra-arterial, IV intravenous, JAMA Journal of the American Medical Association, NEJM New England Journal of Medicine, NZ New Zealand, tPA alteplase, US United States, UK United Kingdom